Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

BIOALLIANCE PHARMA SA (C4X)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (EUR)
Sales 2018 2,20 M
EBIT 2018 -18,2 M
Net income 2018 -14,9 M
Finance 2018 11,3 M
Yield 2018 -
Sales 2019 3,00 M
EBIT 2019 -9,00 M
Net income 2019 -9,00 M
Debt 2019 3,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 28,1x
EV / Sales2019 25,4x
Capitalization 73,2 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
05/04Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
03/29ONXEO : Annual results
CO
01/23ONXEO : Financial Agenda 2018
PU
2017ONXEO : Establishes Scientific Advisory Board with International Experts in DNA-..
PU
2017Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Infor..
GL
2017Onxeo Reports First Instance Decision from the Commercial Court of Paris in t..
GL
2017Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oli..
GL
2017ONXEO : Patent Issued for Nanoparticles Loaded with Chemotherapeutic Antitumoral..
AQ
2017ONXEO : announces compelling preclinical data in combination for its two innovat..
PU
2017Onxeo announces compelling preclinical data in combination for its two innov..
GL
2017ONXEO : Grants Exclusive Worldwide License of Validive Developed for the Treatme..
AQ
More news
Sector news : Pharmaceuticals - NEC
02:44pShire receives new bid from Takeda as takeover deadline looms
RE
02:33pASTRAZENECA : raises stake in respiratory partner Circassia
RE
02:25pINVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
02:02pSHIRE PLC SHIRE PLC : Statement Re Revised -2-
DJ
02:02pSHIRE PLC SHIRE PLC : Statement Re Revised Proposal
DJ
More sector news : Pharmaceuticals - NEC
Chart BIOALLIANCE PHARMA SA
Duration : Period :
BioAlliance Pharma SA Technical Analysis Chart | C4X | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 2
Average target price 1,55 €
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA89
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%192 109
MERCK AND COMPANY7.07%158 571